Financial Performance - The company expects a net profit attributable to shareholders of approximately RMB 14,000 to 18,000 million for 2024, representing a decline of 57% to 67% compared to the previous year[2]. - The net profit after deducting non-recurring gains and losses is projected to be between RMB 11,000 and 15,000 million, reflecting a decrease of 74% to 81% year-on-year[2]. - The estimated operating revenue for 2024 is around RMB 286,000 million, down from RMB 411,377.23 million in the previous year[2]. - The company anticipates non-recurring gains and losses of about RMB 3,200 million for 2024, compared to -RMB 15,400 million in the previous year[5]. Overseas Business Performance - The company’s overseas business achieved operating revenue of approximately RMB 53,400 million, marking a growth of about 96% compared to the previous year[5]. Research and Development - Research and development expenses decreased by approximately RMB 15,900 million, while R&D investment remains around 20% of operating revenue[5]. - The company has terminated certain R&D projects to focus on core product development while ensuring necessary R&D investments[5]. Market Challenges - The decline in domestic sales revenue is attributed to a decrease in the number of newborns and intensified market competition[4]. Asset Management - The fair value loss from financial assets is estimated at approximately RMB 9,700 million due to stock price declines[5]. - The company conducted impairment testing on assets, resulting in an impairment loss of about RMB 15,900 million[5].

证券代码：300142 证券简称：沃森生物 | --- | --- | --- | --- | --- | |-------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------|-------|----------------------------------------------------------| | 投资者关系活动 类别 | √ 特定对象调研 □ \n□ 媒体采访 □ □ 新闻发布会 □ □ 现场参观 □ 其他（ ） 嘉实基金 李慧 | 分析师会议 \n业绩说明会 路演活动 | | | | 参与单位名称及 人员姓名 | 融通基金 刘 ...

证券代码：300142 证券简称：沃森生物 公告编号：2024-084 云南沃森生物技术股份有限公司 破伤风是由产毒破伤风杆菌引起的急性感染性疾病，该菌芽孢可在任何地理 环境中生存，可通过被污染的皮肤创口或受损组织（包括穿刺伤）进入人体。该病 见于各个年龄，即使在重症监护下其病死率仍然很高。在世界上很多免疫规划不完 善的地区，特别是低收入国家中最不发达地区，破伤风仍然是重要的公共卫生问 题。吸附破伤风疫苗为公司自主研发的一款预防破伤风梭状芽孢杆菌感染的疫苗， 接种本疫苗后，可刺激机体产生免疫应答，用于预防破伤风。 关于收到吸附破伤风疫苗《药物临床试验批准通知书》的公告 根据中国食品药品检定研究院相关公示信息显示，自 2021 年至 2024 年三季 度，全国吸附破伤风疫苗批签发总批次为 162 批。 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 本疫苗获批进入临床试验，对公司近期业绩不会产生大的影响。后续公司将尽 快按照国家关于注册临床试验的有关规定，以及本疫苗临床试验批准通知书的具 体要求，积极组织开展本疫苗临床试验。根据我国药品注册的有关要求，该疫苗确 ...

云南沃森生物技术股份有限公司 证券代码：300142 证券简称：沃森生物 公告编号：2024-083 关于 2024 年第三季度计提信用减值准备、资产减值准备的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 云南沃森生物技术股份有限公司（以下简称"公司"）于 2024 年 10 月 25 日召开第五届董事会第二十四次会议和第五届监事会第十八次会议，审议通过了 《关于 2024 年第三季度计提信用减值准备、资产减值准备的议案》。根据《深 圳证券交易所创业板股票上市规则》《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》《深圳证券交易所创业板上市公司自律监管 指南第 1 号——业务办理》《企业会计准则》等相关规定的要求，公司及下属子 公司对 2024 年第三季度末各类存货、应收账款、其他应收款、应收退货成本、 固定资产、在建工程、长期股权投资、无形资产、金融资产及商誉等资产进行了 全面清查，对各类存货的可变现净值，应收款项回收的可能性，固定资产、在建 工程、金融资产及无形资产等的可变现性进行了充分的评估和分析，认为上述资 产中部分资产 ...

Financial Performance - Revenue for Q3 2024 was CNY 707,997,626.68, a decrease of 28.51% compared to the same period last year[2] - Net profit attributable to shareholders for Q3 2024 was CNY 85,798,163.00, down 12.57% year-over-year[2] - Net profit excluding non-recurring items for Q3 2024 was CNY 77,964,589.50, a decline of 42.60% compared to the previous year[2] - The company's revenue for the third quarter was CNY 214,134.62 million, a decrease of 32.19% compared to CNY 315,804.44 million in the previous year[10] - The net cash flow from operating activities decreased by 35.02% to CNY 55,940.46 million, down from CNY 86,093.63 million in the same period last year[12] - The company reported a significant increase in non-operating income, which rose to CNY 12,692.41 million, a 13,501.19% increase due to the completion of project funding settlement[11] - The company experienced a 681.19% increase in asset impairment losses, totaling CNY -9,821.07 million, attributed to market competition and sales forecast changes[11] - The income tax expense decreased by 69.93% to CNY 2,314.83 million, reflecting a reduction in total profit[11] - The net profit for Q3 2024 was CNY 350,640,884.90, a decrease of 49.7% compared to CNY 697,229,401.89 in Q3 2023[27] - Operating profit for Q3 2024 was CNY 286,082,966.34, down 63.3% from CNY 779,311,646.09 in the same period last year[27] - The total comprehensive income for Q3 2024 was CNY 350,640,884.90, compared to CNY 697,229,401.89 in the same period last year[27] Assets and Liabilities - Total assets at the end of Q3 2024 were CNY 15,003,709,002.89, representing a decrease of 3.75% from the end of the previous year[2] - The company's total liabilities decreased to RMB 3.27 billion from RMB 4.19 billion, a reduction of approximately 21.8%[25] - As of the end of Q3 2024, total current assets decreased to RMB 7.40 billion from RMB 8.73 billion at the beginning of the year, representing a decline of approximately 15.3%[23] - The total non-current assets increased to RMB 7.61 billion from RMB 6.86 billion, marking an increase of about 10.7%[24] Shareholder Information - The total number of common shareholders at the end of the reporting period is 117,751[14] - Liu Junhui holds 3.12% of shares, totaling 49,959,914 shares[14] - The top ten shareholders collectively hold significant stakes, with the largest shareholder holding 3.12%[14] - The total number of restricted shares at the beginning of the period was 39,823,007, with 777,787 shares released during the period[15] - The total number of restricted shares at the end of the period is 40,139,868[15] - The largest shareholder, Liu Junhui, holds 49,959,914 shares through a combination of accounts[14] - The company has a significant number of shares under lock-up due to executive restrictions, with 75% of holdings locked annually[15] - The report indicates no changes in the top ten shareholders due to lending or returning shares[15] - The company has a diverse shareholder base, including both domestic and foreign entities[14] - The report highlights the importance of shareholder structure in corporate governance and decision-making[14] Cash Flow and Investments - Cash flow from operating activities for the year-to-date was CNY 559,404,641.37, down 35.02% year-over-year[2] - The net cash flow from investing activities showed a significant decline of 104.17%, amounting to CNY -117,242.54 million, due to reduced investment returns and increased fixed deposits[12] - The company reported a cash outflow from investing activities of CNY 1,172,425,353.59, compared to CNY 574,228,118.23 in Q3 2023[30] - Cash and cash equivalents at the end of Q3 2024 were CNY 3,618,412,563.93, down from CNY 4,073,223,661.92 at the end of Q3 2023[30] Share Repurchase and Capital Changes - The company completed a share repurchase plan, acquiring a total of 5,999,943 shares at a total cost of approximately RMB 258.26 million, with a maximum price of RMB 49.85 per share[16] - In 2023, the company initiated a new share repurchase plan with a maximum of 400,000 shares and a maximum price of RMB 50 per share, ultimately repurchasing 2,000,000 shares at a total cost of approximately RMB 72.20 million[17] - The company has completed the cancellation of 2,000,000 shares repurchased in 2023, reducing its total share capital from 1,607,348,484 shares to 1,605,348,484 shares[18] - The company also canceled 5,999,943 shares repurchased in 2022, further reducing its total share capital to 1,599,348,541 shares[18] - The company's registered capital decreased from RMB 1,607,348,484 to RMB 1,599,348,541 following the cancellation of repurchased shares[18] Future Financing Plans - The company decided to terminate the issuance of convertible bonds originally planned for a total amount of up to RMB 1.24 billion due to current market conditions and business development considerations[19] - The company extended the validity period for the convertible bond issuance plan until August 25, 2024, before ultimately deciding to withdraw the application[20] - The company plans to issue shares to specific targets with a total financing amount not exceeding RMB 300 million, which is 20% of the company's net assets as of the end of the last fiscal year[22] Operating Costs and Expenses - Operating costs decreased to RMB 1.76 billion from RMB 2.32 billion, a reduction of approximately 24.2%[26] - R&D expenses for the current period were RMB 431.1 million, down from RMB 573.4 million, indicating a decrease of about 24.8%[26] - The financial expenses decreased by 43.50% to CNY -3,005.02 million, influenced by reduced interest income from bank deposits[10] - The company incurred financial expenses of CNY 30,050,150.16, a decrease from CNY 53,189,158.04 in the previous year[27]

云南沃森生物技术股份有限公司 信息披露管理制度 云南沃森生物技术股份有限公司 信息披露管理制度 第一章 总则 第一条 为规范公司的信息披露行为，加强信息披露事务管理，确保信息 披露的公平性，保护投资者合法权益，根据《中华人民共和国公司法》（以下简 称"《公司法》"）、《中华人民共和国证券法》（以下简称"《证券法》"）、 《上市公司信息披露管理办法》《深圳证券交易所创业板股票上市规则》（以下 简称"《上市规则》"）等相关法律法规、部门规章、规范性文件和《云南沃森 生物技术股份有限公司章程》（以下简称"《公司章程》"）的规定，结合公司 实际情况，特制定本制度（以下简称"本制度"）。 第二条 本制度对公司股东、全体董事、监事、高级管理人员和公司各部 门（含子公司）具有约束力。 第二章 信息披露的基本原则 第九条 公司及相关信息披露义务人应按照本制度规定，主动、及时、完 整地披露可能对公司股票价格及其衍生品种交易价格或者投资决策产生较大影 响的重大信息，不得延迟披露，不得有意选择披露时点强化或淡化信息披露效果， 造成实际上的不公平。 处于筹划阶段的重大事件，公司及相关信息披露义务人应采取保密措施，尽 量减少知情人员范 ...

云南沃森生物技术股份有限公司 重大信息内部报告制度 云南沃森生物技术股份有限公司 重大信息内部报告制度 第一章 总则 第一条 为加强云南沃森生物技术股份有限公司（以下简称"公司"）重大 事件信息内部报告管理，明确公司重大事件内部报告的方法和流程，确保公司合 法、真实、准确、完整、及时地披露重大事件的相关信息，根据《中华人民共和 国公司法》（以下简称"《公司法》"）、《中华人民共和国证券法》（以下简称"《证 券法》"）、《深圳证券交易所创业板上市规则》（以下简称"《上市规则》"）、《上市 公司治理准则》及其他有关法律、法规、部门规章、规范性文件和《云南沃森生 物技术股份有限公司章程》（以下简称"《公司章程》"）的规定，结合公司实际情 况，特制定本制度。 第二条 本制度所指"重大信息"是指对公司股票价格及其衍生品种交易 价格或者投资决策可能或者已经产生较大影响的尚未公开的信息。 尚未公开是指公司尚未在符合中国证券监督管理委员会（以下简称"中国证 监会"）规定条件的媒体及深圳证券交易所（以下简称"深交所"）网站（以下 统称"符合条件媒体"）上公开披露。 第三条 公司重大信息内部报告制度是指当出现、发生或即将发生本制 ...

证券代码：300142 证券简称：沃森生物 公告编号：2024-080 云南沃森生物技术股份有限公司 第五届监事会第十八次会议决议公告 本公司及监事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 云南沃森生物技术股份有限公司（以下简称"公司"）第五届监事会第十八 次会议于 2024 年 10 月 25 日在公司会议室召开，会议通知于 10 月 18 日以电子 邮件方式发出。本次会议以现场会议结合通讯表决的方式召开，应参加会议监事 3 人，实际参加会议监事 3 人。会议由监事会主席丁世青女士主持。本次会议的 召集、召开符合《公司法》及《公司章程》的规定。 二、监事会会议审议情况 1、审议通过了《关于<2024 年第三季度报告>的议案》 监事会对公司《2024 年第三季度报告》进行审核后，发表如下审核意见： 董事会编制和审议公司《2024 年第三季度报告》的程序符合法律、行政法规和 中国证监会的规定；公司《2024 年第三季度报告》的内容和格式符合中国证监 会和深圳证券交易所的规定；报告内容真实、准确、完整地反映了公司报告期内 的实际情况，不存在任何虚 ...

第五届董事会第二十四次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 证券代码：300142 证券简称：沃森生物 公告编号：2024-079 云南沃森生物技术股份有限公司 一、董事会会议召开情况 云南沃森生物技术股份有限公司（以下简称"公司"）第五届董事会第二十 四次会议于 2024 年 10 月 25 日在公司会议室召开，会议通知于 10 月 18 日以电 子邮件方式发出。本次会议以现场会议结合通讯表决的方式召开，应参加会议董 事 11 人，实际参加会议董事 11 人。会议由董事长李云春先生主持，公司部分监 事、高级管理人员列席会议。本次会议的召集、召开符合《公司法》及《公司章 程》的规定。 二、董事会会议审议情况 1、审议通过了《关于<2024 年第三季度报告>的议案》 表决结果：同意 11 票，反对 0 票，弃权 0 票。 本议案获得通过。 公司《2024年第三季度报告》详见证监会指定的创业板信息披露网站巨潮资 讯网。 2、审议通过了《关于 2024 年第三季度计提信用减值准备、资产减值准备的议 案》 董事会同意公司根据《企业会计准则》《深 ...

Group 1: General Principles of Investor Relations Management - The purpose of investor relations management is to enhance communication between the company and investors, maximizing company value and shareholder interests [1] - The basic principles include compliance, equality, proactivity, and honesty [1][3] - The company must provide objective, accurate, and complete information about its actual situation to avoid misleading investors [1][4] Group 2: Responsibilities and Structure - The board secretary is designated as the head of investor relations management, responsible for planning and organizing related activities [2][5] - Personnel involved in investor relations must possess good character, knowledge, and communication skills [5][6] - The board office serves as the functional department for investor relations management, ensuring timely and effective communication with investors [7][8] Group 3: Communication Methods - Communication methods with investors include announcements, shareholder meetings, one-on-one communications, and company websites [3][4] - The company must disclose information on designated websites and newspapers, ensuring no prior disclosure through other means [4][10] - Annual performance briefings must be held within a specified timeframe after the annual report is released [4][10] Group 4: Event Management and Compliance - Specific protocols are in place for receiving investors and analysts, including prior appointment and signing of commitment letters [9][10] - The company must avoid disclosing any undisclosed significant information during investor relations activities [10][11] - All investor relations activities must be documented and retained for a minimum of ten years [9][10]